Subscribe: MedWorm: Benign Prostatic Hyperplasia
http://www.medworm.com/rss/medicalfeeds/conditions/Benign-Prostatic-Hyperplasia.xml
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
benign prostatic  benign  bph  cancer  hyperplasia  patients  prostate cancer  prostate  prostatic hyperplasia  prostatic  source 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: MedWorm: Benign Prostatic Hyperplasia

MedWorm: Benign Prostatic Hyperplasia



MedWorm.com provides a medical RSS filtering service. Over 7000 RSS medical sources are combined and output via different filters. This feed contains the latest news and research in the Benign Prostatic Hyperplasia category.



Last Build Date: Mon, 21 Mar 2016 20:00:49 +0100

 



Progression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes.

Mon, 21 Mar 2016 05:47:03 +0100

Authors: Norström MM, Rådestad E, Sundberg B, Mattsson J, Henningsohn L, Levitsky V, Uhlin M Abstract Benign prostatic hyperplasia (BPH) is a common chronic non-malignant condition whose prevalence substantially increases with age. Immune cell infiltration and pro-inflammatory mediators have been implicated in the pathogenesis. Here, we characterized 21 extracellular markers on prostate-infiltrating lymphocytes (PILs) and analyzed expression of 26 soluble proteins in prostate tissue obtained from BPH patients (n = 31). These data were correlated with clinical parameters and compared with peripheral blood mononuclear cells (PBMCs) (n = 10). Increased frequencies of T cells expressing co-inhibitory receptors LAG-3, PD-1, TIM-3 or CTLA-4, and co-stimulatory receptors CD28, OX40 or 4...

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Implication of Rho‐kinase and soluble guanylyl cyclase enzymes in prostate smooth muscle dysfunction in middle‐aged rats

Mon, 21 Mar 2016 00:00:00 +0100

ConclusionsProstate hypercontractility in middle‐aging is associated with increased release of noradrenaline and Rho‐kinase pathway, as well as with impairments of NO‐sGC and β‐adrenoceptor pathways. Middle‐aged rats are suitable to explore the enhanced prostatic tone in the absence of prostate overgrowth. Neurourol. Urodynam. © 2016 Wiley Periodicals, Inc. (Source: Neurourology and Urodynamics)



Unseen Perils of Urinary Catheters

Sun, 20 Mar 2016 13:20:15 +0100

A 68-year-old man with a history of multiple comorbidities and health problems, including benign prostatic hyperplasia (BPH) with urinary retention, was admitted to the hospital. The patient required total care and was incontinent of bowel and bladder. Although alert and oriented to person and place, he was only able to answer simple yes-or-no questions. (Source: AORN Journal)



miR-218 impedes IL-6-induced prostate cancer cell proliferation and invasion via suppression of LGR4 expression.

Sat, 19 Mar 2016 17:53:03 +0100

Authors: Li F, Gu C, Tian F, Jia Z, Meng Z, Ding Y, Yang J Abstract Prostate cancer is the most common solid-organ malignancy and the second leading cause of cancer-related death in males. The oncogenic effect of leucine-rich repeat-containing G protein-coupled receptor (LGR) 4 has been recognized in the formation of various types of cancers, yet its regulatory mechanism in prostate cancer is still not fully understood. Previous study has shown that LGR4 may be a new responsive gene of interleukin-6 (IL-6) in cancer progression. In the present study, we established the LNCaP-IL-6+ cell subline by long-term incubation with a low concentration of IL-6 and explored the regulatory role of miR-218, a tumor-suppressing miRNA, in IL-6-induced LGR4 expression and LNCaP-IL-6+ cell prolife...



A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia

Thu, 17 Mar 2016 00:00:00 +0100

Conclusion: Alfuzosin, tamsulosin, and silodosin showed similar efficacy in improvement of LUTS secondary to BPH, with good tolerability, acceptability, and minimum hemodynamic adverse effects. Alfuzosin, tamsulosin, and silodosin are comparable in efficacy in symptomatic management of BPH. The occurrence of QTc prolongation in three subjects with tamsulosin in the present study is an unexpected adverse event as there are no reports of QTc prolongation with tamsulosin in any of the previous studies. (Source: Indian Journal of Pharmacology)



Re: Drug Adherence and Clinical Outcomes for Patients under Pharmacological Therapy for Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia: Population-Based Cohort Study

Wed, 16 Mar 2016 00:00:00 +0100

L. Cindolo, L. Pirozzi, C. Fanizza, M. Romero, A. Tubaro, R. Autorino, C. De Nunzio and L. Schips (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.







Androgen receptor‐related diseases: what do we know?

Wed, 16 Mar 2016 00:00:00 +0100

Summary The androgen receptor (AR) and the androgen–AR signaling pathway play a significant role in male sexual differentiation and the development and function of male reproductive and non‐reproductive organs. Because of AR's widely varied and important roles, its abnormalities have been identified in various diseases such as androgen insensitivity syndrome, spinal bulbar muscular atrophy, benign prostatic hyperplasia, and prostate cancer. This review provides an overview of the function of androgens and androgen–AR mediated diseases. In addition, the diseases delineated above are discussed with respect to their association with mutations and other post‐transcriptional modifications in the AR. Finally, we present an introduction to the potential therapeutic application of most rec...



Efficacy of Adding Dutasteride to α‐Blocker Therapy Treated Benign Prostatic Hyperplasia Patients with Small Volume Prostate (

Wed, 16 Mar 2016 00:00:00 +0100

Conclusions:Benign prostatic hyperplasia in LUTS patients with small prostates did not show a sustainable benefit from the addition of dutasteride to α‐blocker therapy. (Source: LUTS: Lower Urinary Tract Symptoms)



Different laser prostatectomy for benign prostatic hyperplasia: What is the role of outcome-effectiveness analysis in clinical practice?

Tue, 15 Mar 2016 00:00:00 +0100

Publication date: Available online 15 March 2016 Source:Urological Science Author(s): Ke-Hung Tsui (Source: Urological Science)



The European Association of Urology Upgrades UroLift(R) System Trial Data to its Highest Possible Classification - Level 1A - in its Guidelines

Mon, 14 Mar 2016 13:31:51 +0100

Further evidence from two multi-national randomized studies presented at EAU conference supports durability of UroLift® System treatment for men with enlarged prostate MUNICH, March 14, 2016 -- (Healthcare Sales & Marketing Network) -- The UroLift ... Devices, UrologyNeoTract, UroLift, Benign Prostatic Hyperplasia (Source: HSMN NewsFeed)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




NeoTract launches MedLift trial

Fri, 11 Mar 2016 22:45:45 +0100

NeoTract said Monday it enrolled the 1st patient in its MedLift U.S. investigational device exemption trial of its UroLift system for treating patients with benign prostatic hyperplasia. The new study from Pleasanton, Calif.-based NeoTract will be conducted across 8 sites in the U.S. and will examine the safety and efficacy of the UroLift system for treating patients with BPH who have an obstructive median lobe, which the company says is currently contraindicated in the U.S. “Unlike other BPH procedures, the UroLift System directly opens the urethra without cutting, heating, or removing prostate tissue. In this way patients experience very rapid and durable relief. This treatment option has been very successful for many of my BPH patients who are unhappy with medical therapy and conc...



Assessment of energy density usage during 180W lithium triborate laser photo‐selective vaporization of the prostate for benign prostatic hyperplasia. Is there an optimal amount of kilo‐Joules per gram of prostate?

Fri, 11 Mar 2016 15:07:05 +0100

ConclusionIncreased energy usage per cc of prostate is associated with a more significant PSA reduction (>50%) at 6,12 and 24 months suggesting increased vaporization of adenoma tissue. However this did not translate into differences in functional outcomes at two years of follow‐up.This article is protected by copyright. All rights reserved. (Source: BJU International)



Detection of miRNAs in urine of prostate cancer patients

Fri, 11 Mar 2016 00:00:00 +0100

Conclusions Measurement of urinary levels of PCa-specific miRNAs could assist in more specific detection of PCa and prediction of BCR. (Source: Medicina)



Pumpkin seed extract: Cell growth inhibition of hyperplastic and cancer cells, independent of steroid hormone receptors.

Fri, 11 Mar 2016 00:00:00 +0100

Authors: Medjakovic S, Hobiger S, Ardjomand-Woelkart K, Bucar F, Jungbauer A Abstract Pumpkin seeds have been known in folk medicine as remedy for kidney, bladder and prostate disorders since centuries. Nevertheless, pumpkin research provides insufficient data to back up traditional beliefs of ethnomedical practice. The bioactivity of a hydro-ethanolic extract of pumpkin seeds from the Styrian pumpkin, Cucurbita pepo L. subsp. Pepo var. styriaca, was investigated. As pumpkin seed extracts are standardized to cucurbitin, this compound was also tested. Transactivational activity was evaluated for human androgen receptor, estrogen receptor and progesterone receptor with in vitro yeast assays. Cell viability tests with prostate cancer cells, breast cancer cells, colorectal adenocarcino...



Detecting benign prostatic hyperplasia in dogs

Thu, 10 Mar 2016 00:00:00 +0100

Biobest Laboratories is offering the canine prostate specific arginine esterase (CPSE) test to help detect benign prostatic hyperplasia (BPH) in dogs. The company explains that BPH is a common problem in older entire male dogs but that it is not easily differentiated from more serious prostatic conditions on clinical grounds alone. It says that the CPSE test is a simple and convenient blood test (requiring 1 ml of plasma or 2 ml of clotted blood) that can be used as part of an annual check up to look for preclinical BPH in entire male dogs or to determine whether a dog presenting with signs of prostatic disease is most likely to be suffering from BPH or from a more serious condition requiring further investigation. The test can also be used to monitor treatment of BPH. Address: B...

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Evaluation of Vitronectin Expression in Prostate Cancer and the Clinical Significance of the Association of Vitronectin Expression with Prostate Specific Antigen in Detecting Prostate Cancer.

Wed, 09 Mar 2016 20:56:03 +0100

CONCLUSION: VTN levels in sera may be used as a potential marker of PCa for the diagnosis and assessment of disease progression and metastasis. The combined detection of VTN and PSA in sera can be clinically applied in PCa diagnosis. . PMID: 26945657 [PubMed - in process] (Source: Urology Journal)



Effects of dutasteride on serum free‐testosterone and clinical significance of testosterone changes

Tue, 08 Mar 2016 00:00:00 +0100

Summary Sixty‐two patients with benign prostate hyperplasia (BPH) who were being treated with dutasteride participated in this study. Prostate volume, uroflowmetry, blood tests, the International Prostate Symptom Score (IPSS) and International Index of Erectile Function (IIEF‐5) were determined before and 1, 3 and 12 months after the treatment with dutasteride. Patients were divided into two groups based on changes in serum testosterone after 1 month: Group A (>20% increase; n = 33) or Group B (<20% increase; n = 29). Serum free‐testosterone levels were 20.4% higher after 1 month and remained constant thereafter. When Groups A and B were compared, baseline free‐testosterone levels were significantly lower in Group A, IPSS QOL was significantly better in Group A at 3 an...



The prostate cancer immunome: in silico functional analysis of antigenic proteins from microarray profiling with IgG

Tue, 08 Mar 2016 00:00:00 +0100

This article is protected by copyright. All rights reserved (Source: Proteomics)






Reply to Second Letter to the Editor Regarding the Article: the Prevalence and Association of Varicoceles on Male Patients with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms

Mon, 07 Mar 2016 00:00:00 +0100

We read the letter seriously, as we did with the first letter. We have already noticed that our conclusions were inconsistent with those in the study by Otunctemur et al.1, 2 The reasons for this inconsistency may be as follows. First, there might be some differences in race, life-style, environment, and other related factors. Second, age distribution differences were observed. The mean ages of grade 1, 2, and 3 varicocele patients were 65.43, 67.15, and 64.52 years in our study and were 58.79, 60.30, and 61.60 years in Otunctemur et al.'s study. (Source: Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.










BPH update: medical versus interventional management.

Tue, 01 Mar 2016 11:13:02 +0100

Authors: Blankstein U, Van Asseldonk B, Elterman DS Abstract Benign prostatic hyperplasia (BPH) is a common condition that afflicts a large proportion of aging men. The primary care physician has an important role with the identification and early treatment of bothersome urinary symptoms caused by BPH. This includes a detailed history and physical exam, as well as initiation of a number of medications such as alpha-blockers, 5-alpha reductase inhibitors and phosphodiesterase-5 inhibitors. It is also very important for the primary care giver to determine when additional evaluation and referral to a urologist needs to occur, specifically when surgical intervention is needed. This review will summarize the management of this common disorder and is designed to aid the generalist with t...



Differentiating Transition Zone Cancers From Benign Prostatic Hyperplasia by Quantitative Multiparametric Magnetic Resonance Imaging

Tue, 01 Mar 2016 06:00:00 +0100

Conclusions: Apparent diffusion coefficient may play a role in distinguishing TZ cancers from non-encapsulated BPH nodules that closely resemble cancer. (Source: Journal of Computer Assisted Tomography)



The association of eNOS G894T gene polymorphisms with responsiveness to α1‐blocker in men with BPH/LUTS

Tue, 01 Mar 2016 00:00:00 +0100

ConclusionsThe presence of eNOS 894T allele had a significantly negative impact on responsiveness to α1‐blocker in BPH/LUTS treatment, suggesting that eNOS G894T gene polymorphisms may play an implication as a genetic susceptibility factor for drug efficacy in men with BPH/LUTS.This article is protected by copyright. All rights reserved. (Source: BJU International)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study)

Tue, 01 Mar 2016 00:00:00 +0100

ConclusionsSilodosin improved lower urinary tract symptoms in three out of four patients, including diurnal voiding and storage symptoms, nocturia, and quality of life. This treatment showed a favorable safety profile in this setting. (Source: International Journal of Urology)



Blockade of Androgen Markers Using a Novel Betasitosterol, Thioctic Acid and Carnitine‐containing Compound in Prostate and Hair Follicle Cell‐based Assays

Tue, 01 Mar 2016 00:00:00 +0100

Androgenetic alopecia (AGA) affects approximately 70% of men and 40% of women in an age‐dependent manner and is partially mediated by androgen hormones. Benign prostatic hyperplasia (BPH) similarly affects 50% of the male population, rising by 10% each decade. Finasteride inhibits 5‐alpha reductase (5AR) and is used to treat both disorders, despite offering limited clinical benefits accompanied by significant adverse side effects. Building on our previous work demonstrating the efficacy of naturally derived 5AR inhibitors (such as stigmasterol and beta sitosterol), we hypothesize that targeting 5AR as well as inflammatory pathways may yield improved efficacy in AGA and BPH. Here we address these dual pathomechanisms by examining the potency of a novel composition using in vitro assays ...



A review of the efficacy and safety of mirodenafil in the management of erectile dysfunction

Mon, 29 Feb 2016 00:00:00 +0100

Erectile dysfunction (ED) is a common disorder that can jeopardize quality of life and the partnership of patients and their sexual partners. The advent of oral phosphodiesterase type 5 inhibitors (PDE5Is) has revolutionized a treatment for ED, and they are recognized as the first-line therapy for ED, regardless of its etiology. Mirodenafil, a second-generation PDE5I, has biochemical profiles such as high affinity for PDE5 and high selectivity for PDE5 over other PDE isoforms, compared to other existing PDE5Is such as sildenafil, vardenafil and tadalafil. Available evidence has suggested that doses of 50 and 100 mg mirodenafil effectively improve ED [with improvements in the erectile function domain of the International Index of Erectile Function (IIEF-EF) scores, positive responses to que...



An update on the role of testosterone replacement therapy in the management of hypogonadism

Mon, 29 Feb 2016 00:00:00 +0100

While US testosterone prescriptions have tripled in the last decade with lower trends in Europe, debate continues over the risks, benefits and appropriate use of testosterone replacement therapy (TRT). Some authors blame advertising and the availability of more convenient formulations whilst other have pointed out that the routine testing of men with erectile dysfunction (a significant marker of cardiovascular risk) and those with diabetes would inevitably increase the diagnosis of hypogonadism and lead to an increase in totally appropriate prescribing. They commented that this was merely an appropriate correction of previous underdiagnosis and undertreatment by adherence to evidence-based guidelines. Urologists and primary care physicians are the most frequent initiators of TRT, usually f...



Cyclooxygenase 2 (rs2745557) Polymorphism and the Susceptibility to Benign Prostate Hyperplasia and Prostate Cancer in Egyptians.

Fri, 26 Feb 2016 00:00:00 +0100

Authors: Fawzy MS, Elfayoumi AR, Mohamed RH, Fatah IR, Saadawy SF Abstract Cyclooxygenase-2 (COX-2), an inducible isoform of cyclooxygenase, has been reported to be correlated with tumorigenesis, tumor progression, and metastasis. We aimed to evaluate the association between COX-2 (rs2745557) polymorphism and prostate cancer (PCa), benign prostate hyperplasia (BPH) risk. We also assessed the influence of other risk factors such as obesity, smoking, diabetes in modulating the risk of PCa in Egyptian men. COX-2 (rs2745557) was genotyped in 112 PC patients, 111 BPH and 120 subjects as a control group. COX-2 and PSA levels were measured by ELISA. We found that GG genotype was associated with a 17-fold increased risk for PCa and 20-fold increased the risk for BPH more than AA genotype. ...

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Coordinated induction of cell survival signaling in the inflamed microenvironment of the prostate

Wed, 24 Feb 2016 11:20:04 +0100

CONCLUSIONSThe prostate responds to deleterious inflammation with induction of cell survival mechanisms, most notably survivin and autophagy, demonstrating a coordinated induction of survival factors that protects and expands a specialized set of prostatic epithelial cells as part of the repair and recovery process during inflammation. Prostate © 2016 Wiley Periodicals, Inc. (Source: The Prostate)



Altered expression of p53, but not Rb, is involved in canine prostatic carcinogenesis

Wed, 24 Feb 2016 00:00:00 +0100

Publication date: Available online 23 February 2016 Source:Research in Veterinary Science Author(s): Simone Pagliarone, Luca Frattone, Valeria Pirocchi, Leonardo Della Salda, Chiara Palmieri Abnormalities in the retinoblastoma (Rb) and p53 tumour suppressor gene have been frequently detected in human and canine cancers, but never investigated in canine prostate cancer, considered a good model for the advanced and aggressive androgen-resistant prostate cancer in men. Therefore, the aim of this study was to evaluate the immunohistochemical expression of Rb and p53 in 6 normal canine prostates, 15 canine prostates with benign prostatic hyperplasia (BPH) and 10 prostatic carcinomas (PCs). In all normal samples, p53 was expressed in low number of epithelial cells, while a greater number ...



Uric acid: a modulator of prostate cells and activin sensitivity.

Wed, 24 Feb 2016 00:00:00 +0100

This study shows for the first time that a change in plasma or intracellular urate levels, possibly involving GLUT9 and a urate efflux transporter, has an impact on prostate cancer cell growth, and that lowering SUA levels in prostate cancer is likely to be therapeutically beneficial. PMID: 26910779 [PubMed - as supplied by publisher] (Source: Molecular and Cellular Biochemistry)



Benign prostatic hyperplasia, metabolic syndrome and androgenic alopecia: Is there a possible relationship?

Tue, 23 Feb 2016 00:00:00 +0100

Conclusions Dermatologists, urologists, and primary care physicians should monitor patients with early onset AGA for the development of urinary symptoms, to permit an earlier diagnosis of BPH; and for metabolic syndrome symptoms, to permit early diagnosis of cardiovascular risk factors. (Source: Arab Journal of Urology)



Holmium laser enucleation of the prostate for treatment for large-sized benign prostate hyperplasia; is it a realistic endourologic alternative in developing country?

Mon, 22 Feb 2016 22:19:47 +0100

Conclusion In high-volume hospital, HoLEP procedure seems to be equally safe and effective as TVOP with the advantages of minimally invasive procedures. Two years after adopting the technique, HoLEP equally costs the hospital as TVOP. Significant hospital cost savings are anticipated in subsequent cases. (Source: World Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Novel potential serological prostate cancer biomarkers using CT100+ cancer antigen microarray platform in a multi-cultural south african cohort.

Fri, 19 Feb 2016 13:16:02 +0100

Authors: Adeola HA, Smith M, Kaestner L, Blackburn JM, Zerbini LF Abstract There is a growing need for high throughput diagnostic tools for early diagnosis and treatment monitoring of prostate cancer (PCa) in Africa. The role of cancer-testis antigens (CTAs) in PCa in men of African descent is poorly researched. Hence, we aimed to elucidate the role of 123 Tumour Associated Antigens (TAAs) using antigen microarray platform in blood samples (N = 67) from a South African PCa, Benign prostatic hyperplasia (BPH) and disease control (DC) cohort. Linear (fold-over-cutoff) and differential expression quantitation of autoantibody signal intensities were performed. Molecular signatures of candidate PCa antigen biomarkers were identified and analyzed for ethnic group variation. Potential can...



Maintaining a Healthy Balance: Targeting TERT to Stem Benign Prostatic Hyperplasia

Fri, 19 Feb 2016 00:00:00 +0100

Publication date: April 2016 Source:European Urology, Volume 69, Issue 4 Author(s): Adam Pickard, Ian G. Mills (Source: European Urology)



High-mobility group box 1 is involved in the development of benign prostatic hyperplasia with chronic prostatic inflammation.

Thu, 18 Feb 2016 05:22:02 +0100

CONCLUSIONS: These findings provide novel insights into the pathogenic role of HMGB1 in BPH with prostatitis, and suggest that HMGB1 is a potential biomarker and therapeutic target for BPH. PMID: 26143661 [PubMed - as supplied by publisher] (Source: Scandinavian Journal of Urology)



Tumor necrosis factor-α expression in patients with obstructive benign prostatic hyperplasia is associated with a higher incidence of asymptomatic inflammatory prostatitis NIH category IV and prostatic calcification.

Thu, 18 Feb 2016 05:22:02 +0100

CONCLUSIONS: In patients with obstructive BPH, prostatic calculi were found on ultrasound in one-third of the cases, and histological NIH category IV prostatitis in two-thirds of cases. The incidence of both prostatitis NIH category IV and TNF-α expression was significantly higher in patients with prostatic calculi than in those without. PMID: 25959105 [PubMed - as supplied by publisher] (Source: Scandinavian Journal of Urology)



Immunohistochemical expression of interleukin-2 receptor and interleukin-6 in patients with prostate cancer and benign prostatic hyperplasia: association with asymptomatic inflammatory prostatitis NIH category IV.

Thu, 18 Feb 2016 05:22:02 +0100

CONCLUSIONS: IL-2R and IL-6 expression was significantly higher in prostate cancer tissue than in normal tissue. Patients with asymptomatic inflammatory prostatitis NIH category IV showed significantly greater activity. PMID: 25363611 [PubMed - indexed for MEDLINE] (Source: Scandinavian Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Immunogenetics of prostate cancer and benign hyperplasia – the potential use of an HLA‐G variant as a tag SNP for prostate cancer risk

Thu, 18 Feb 2016 00:00:00 +0100

In this study, we evaluated the impact of eight polymorphisms at the 3′ untranslated region (3′UTR) of the HLA‐G gene in the development of prostate cancer (PCa) and benign prostatic hyperplasia (BPH). A total of 468 DNA samples of Brazilian men predominantly Euro‐descendant with PCa (N = 187), BPH (N = 152) and healthy control individuals (N = 129) were evaluated. The HLA‐G 3′UTR region was amplified by polymerase chain reaction (PCR), sequenced and genotyped to identify the 14 bp insertion/deletion (rs371194629), +3003T/C (rs1707), +3010C/G (rs1710), +3027A/C (rs17179101), +3035C/T (rs17179108), +3142G/C (rs1063320), +3187A/G (rs9380142) and +3196C/G (rs1610696) polymorphisms. Regression logistic and chi‐square tests were performed to verify the influence of single nucleoti...



Primary diffuse large B-cell lymphoma of the prostate: A report of two cases with diagnostic considerations

Mon, 15 Feb 2016 00:00:00 +0100

We report two cases of primary non-Hodgkin lymphoma of prostate, diffuse large B-cell type, diagnosed on TRUS-guided prostatic biopsies. Correct diagnosis is of crucial importance as the therapeutic strategy for lymphoma is radically different from that for carcinoma, and early detection of prostatic lymphoma can be potentially curative. Thus, knowledge of this rare entity, inclusion in differential diagnosis of lower urinary tract obstruction, and application of an appropriate immunohistochemical panel are essential so as not to miss this unusual diagnosis and to avoid unnecessary surgery. (Source: Journal of Cancer Research and Therapeutics)



Re: Treatment of Benign Prostatic Hyperplasia Using Transurethral Split of the Prostate with a Columnar Balloon Catheter

Mon, 15 Feb 2016 00:00:00 +0100

W. Huang, Y. Guo, G. Xiao and X. Qin (Source: The Journal of Urology)



Re: Impact of Metabolic Syndrome on Response to Medical Treatment of Benign Prostatic Hyperplasia

Mon, 15 Feb 2016 00:00:00 +0100

A. Cyrus, A. Kabir, D. Goodarzi, A. Talaei, A. Moradi, M. Rafiee, M. Moghimi, E. Shahbazi and E. Farmani (Source: The Journal of Urology)



Common Questions About Chronic Prostatitis.

Mon, 15 Feb 2016 00:00:00 +0100

Authors: Holt JD, Garrett WA, McCurry TK, Teichman JM Abstract Chronic prostatitis is relatively common, with a lifetime prevalence of 1.8% to 8.2%. Risk factors include conditions that facilitate introduction of bacteria into the urethra and prostate (which also predispose the patient to urinary tract infections) and conditions that can lead to chronic neuropathic pain. Chronic prostatitis must be differentiated from other causes of chronic pelvic pain, such as interstitial cystitis/bladder pain syndrome and pelvic floor dysfunction; prostate and bladder cancers; benign prostatic hyperplasia; urolithiasis; and other causes of dysuria, urinary frequency, and nocturia. The National Institutes of Health divides prostatitis into four syndromes: acute bacterial prostatitis, chronic bac...

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia.

Sun, 14 Feb 2016 14:09:02 +0100

Authors: Gupta K, Yezdani M, Sotelo T, Aragon-Ching JB Abstract INTRODUCTION: Benign prostatic hyperplasia (BPH) is a common disease among men and significantly impacts quality of life by causing lower urinary tract symptoms (LUTS). Current medical therapies are not always adequate in controlling LUTS or slowing disease progression, and there is unmet need for new effective therapeutic options. AREAS COVERED: The authors review the standard current medical therapies for BPH which include the use of α-1 blockers, 5-α reductase inhibitors, combination therapy and PDE inhibitors. Following this, the authors then discuss new therapies that are currently undergoing preclinical and clinical investigation. EXPERT OPINION: Existing preclinical and clinical trials have highlighted...



Thiazolidinedione and Metformin Use and the Risk of Benign Prostate Hyperplasia in Veterans with Diabetes Mellitus.

Thu, 11 Feb 2016 19:16:02 +0100

CONCLUSIONS: In this large cohort, we observed no association between the use of thiazolidinediones or metformin and new medical or surgical treatment for BPH compared to sulfonylureas. PMID: 25798210 [PubMed - as supplied by publisher] (Source: Journal of Men's Health)



SATB1 promotes prostate cancer metastasis by the regulation of epithelial–mesenchymal transition

Thu, 11 Feb 2016 00:00:00 +0100

In this study SATB1 expression vector or siRNA was employed to modulate the expression level of SATB1 in prostate cancer cells and xenograft tumor in nude mouse model. Immunohistochemical analysis was performed on clinical prostate cancer samples. Silencing SATB1 inhibited the growth of DU-145 cells subcutaneous tumor in nude mice, while SATB1 overexpression promoted the growth of LNCaP cells subcutaneous tumor in nude mice. Immunohistochemical and Western blot analysis of the xenografts showed that silencing SATB1 led to decreased expression of vimentin and MMP2 and increased expression of E-cadherin, while SATB1 overexpression led to increased expression of vimentin and MMP2 and decreased expression of E-cadherin. Furthermore, SATB1, vimentin and MMP2 expression was increased significant...



Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment

Thu, 11 Feb 2016 00:00:00 +0100

ConclusionsThis novel measure of combined response is useful in differentiating patients with clinically relevant symptom improvement for both ED and LUTS/BPH after treatment with tadalafil 5 mg once daily vs placebo. This combined responder measure may be useful in future assessment of treatment benefits across patient groups after various types of treatment intervention (e.g. surgical vs pharmacotherapy vs non‐pharmacological intervention). (Source: BJU International)



Greenlight high-performance system (HPS) 120-W laser vaporization versus transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: a meta-analysis of the published results of randomized controlled trials

Thu, 11 Feb 2016 00:00:00 +0100

Abstract To assess the efficacy and the safety of GreenlightTM high-performance system (HPS) 120-W laser photoselective vaporization of the prostate (PVP) compared with transurethral resection of the prostate (TURP) for treatment of benign prostatic hyperplasia (BPH). The related original studies only including randomized controlled trials were searched by databases MEDLINE, EMBASE, Google Scholar, and the Cochrane Controlled Trial Register. The databases were updated till July 2014. The risk ratio, mean difference, and their corresponding 95 % confidence intervals were calculated. Risk of bias of the enrolled trials were assessed according to Cochrane Handbook. A total of four trials involving 559 patients were enrolled. Statistical analysis was performed by software Review Mana...

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Status and Interrelationship of Zinc, Copper, Iron, Calcium and Selenium in Prostate Cancer.

Wed, 10 Feb 2016 21:35:02 +0100

This study was aimed to detect differential changes and mutual correlations of selected trace elements in prostate cancer tissue versus benign prostatic hyperplasia tissue. Zinc, copper, iron, calcium and selenium were analysed in histologically proven 15 prostate cancer tissues and 15 benign prostatic hyperplasia tissues using atomic absorption spectrophotometer. Unpaired two tailed t test/Mann-Whitney U test and Pearson correlation coefficient were used to compare the level of trace elements, elemental ratios and their interrelations. As compared to benign prostatic tissue, malignant prostatic tissue had significantly lower selenium (p = 0.038) and zinc (p = 0.043) concentrations, a lower zinc/iron ratio (p = 0.04) and positive correlation of selenium with zinc (r = 0.71, p = 0...



Robot-Assisted Bladder Diverticulectomy with Concurrent Management of Bladder Outlet Obstruction

Wed, 10 Feb 2016 12:34:36 +0100

Conclusions: BOO is the main cause of acquired bladder diverticula and is largely due to benign prostatic hyperplasia. Concomitant performance of TUR-P and PVP along with RABD is feasible and safe. Individual catheterization of the diverticulum and bladder facilitates the identification of diverticulum even in the presence of multiple diverticula.Urol Int (Source: Urologia Internationalis)



Recent advances in drug design and drug discovery for androgen- dependent diseases.

Wed, 10 Feb 2016 00:00:00 +0100

This article summarizes the importance of different targets such as 5α-reductase, 17β-HSD, CYP17A, androgen receptor and protein kinase A for the treatment of prostate cancer and benign prostatic hyperplasia. It is a well known fact that dihydrotestosterone (DHT) is associated with the development of androgen-dependent afflictions. At the present time, several research groups are attempting to develop new steroidal and non-steroidal molecules with the purpose of inhibiting the synthesis and biological response of DHT. This review also discusses the most recent studies reported in the literature that describe the therapeutic potential of novel compounds, as well as the new drugs, principally inhibitors of 5α-reductase. PMID: 26861003 [PubMed - as supplied by publisher] (Source: Curre...



Prospective evaluation of prostate with transrectal spectral Doppler with biopsy correlation - A clinico-pathologic study.

Wed, 10 Feb 2016 00:00:00 +0100

CONCLUSION: TR Spectral Doppler parameters did not reveal any significant difference in patients with or without prostatic malignancy, irrespective of Gleason grade. Doppler parameters however, showed significant correlation with age and were lower in younger patients. Advances in Knowledge: TR spectral Doppler is unlikely to emerge as diagnostic and prognostic tool for carcinoma prostate. PMID: 26861745 [PubMed - as supplied by publisher] (Source: The British Journal of Radiology)



Patterns of Care for Newly Diagnosed Benign Prostatic Hyperplasia in the United States

Tue, 09 Feb 2016 00:00:00 +0100

To examine diagnostic tests and treatment patterns in men with new onset benign prostatic hyperplasia (BPH) using consolidated national electronic health record (EHR) data. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Flaxseed reduces epithelial proliferation but does not affect basal cells in induced benign prostatic hyperplasia in rats

Mon, 08 Feb 2016 00:00:00 +0100

Conclusion These results suggest that flaxseed has a protective effect on the prostate epithelium in BPH-induced animals. (Source: European Journal of Nutrition)






Impacts of medical treatments for lower urinary tract symptoms suggestive to benign prostatic hyperplasia on male sexual functions

Mon, 08 Feb 2016 00:00:00 +0100

Publication date: Available online 6 February 2016 Source:Urological Science Author(s): Shih-Tsung Huang Although alpha blockers with or without 5-alpha reductase inhibitors (5-ARIs) have become the standard of treatment for men with moderate to severe lower urinary tract symptoms suggestive to benign prostatic hyperplasia (LUTS/BPH), their negative adverse effects on male sexual functions have become another major issue, which may have a direct impact on patients' quality of life and overall satisfaction. Erectile dysfunction, ejaculation disorders, reduced libido, or anorgasmia have been noted among patients receiving these standards of treatments and these adverse events may be irreversible even after discontinuation of medications. Physicians should inform and discuss with their pat...



Learn More About TURP Procedure for Prostate...

Sun, 07 Feb 2016 00:00:00 +0100

The TURP (transurethral resection of the prostate) procedure commonly used to treat benign prostatic hyperplasia (BPH) can also be used in men with prostate cancer. (Source: About.com Prostate Cancer)



Learn More About Benign Prostatic Hyperplasia

Sat, 06 Feb 2016 00:00:00 +0100

Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate that can cause urinary symptoms identical to prostate cancer. (Source: About.com Prostate Cancer)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 (MAGI-2) in prostate cancer: an immunohistochemical study

Thu, 04 Feb 2016 00:00:00 +0100

Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 (MAGI-2) is a scaffolding protein that links cell adhesion molecules, receptors and signaling molecules to the cytoskeleton and maintains the architecture of cell junctions. MAGI-2 gene rearrangements have recently been described in prostate cancer. We studied the immunohistochemical expression of MAGI-2 protein in prostate tissue. Seventy-eight radical prostatectomies were used to construct three tissue microarrays consisting of 512 1-mm cores, including benign tissue, benign prostatic hyperplasia (BPH), high grade prostatic intraepithelial neoplasia (HGPIN), and adenocarcinoma, Gleason patterns 3-5. (Source: Human Pathology)



De novo steroid biosynthesis in human prostate cell lines and biopsies

Thu, 04 Feb 2016 00:00:00 +0100

CONCLUSIONThese studies question the use of prostate cell lines to study steroid biosynthesis and demonstrate that human prostate samples contain transcripts encoding for key steroidogenic enzymes and proteins indicating that they have the potential to synthesize de novo steroids. We propose CYP17A1 as a candidate enzyme that can be used for patient stratification and treatment in BPH and PCa. Prostate © 2016 Wiley Periodicals, Inc. (Source: The Prostate)



MassDevice.com +3 | The top 3 medtech stories for February 3, 2016

Wed, 03 Feb 2016 20:00:24 +0100

Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.   3. Johnson & Johnson escapes DePuy Pinnacle hip implant lawsuit Johnson & Johnson subsidiary DePuy Orthopaedics won the dismissal of a False Claims Act lawsuit brought by a pair of British surgeons over its since-recalled Pinnacle metal-on-metal hip implant. Drs. Antoni Nargol and David Langton sued in 2012, alleging that DePuy Orthopaedics committed fraud when it billed federal agencies for Pinnacle implantation procedures, because it knew of and conceal...



Urologix sold to settle debt to Medtronic

Wed, 03 Feb 2016 13:03:02 +0100

Urologix Inc. (OCT:ULGX) yesterday said almost all of its assets to a secured creditor, which then sold them to a private company that will operate the business as Urologix LLC. The remnants of Urologix Inc. were renamed 21st North Inc. The Minneapolis-based company, which makes the Cooled ThermoTherapy and Prostiva RF devices to treat benign prostatic hyperplasia, licensed Prostiva from Medtronic (NYSE:MDT). As of March 31, 2015, Urologix owed its Twin Cities neighbor some $2.8 million, according to a regulatory filing, and lacked the scratch to pay up. All of its assets, including intellectual property, were put up as collateral to Medtronic, according to the filing. The nut consisted of a $1.3 million payment due on a $5.3 million promissory note and $1.5 million in royalties and ot...



Mean Platelet Volume May Not Be Related to Benign Prostatic Hyperplasia or Lower Urinary Tract Symptoms

Tue, 02 Feb 2016 19:19:51 +0100

Urol Int (Source: Urologia Internationalis)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Biased α-adrenergic receptor and βarrestin signaling in a cell culture model of benign prostatic hyperplasia.

Tue, 02 Feb 2016 00:00:00 +0100

In this study, we aimed to exploit an in vitro model system of BPH in order to better understand the mechanisms of α-AR signaling in prostatic hyperplasia. PMID: 26850854 [PubMed - as supplied by publisher] (Source: Biochemical and Biophysical Research communications)



Economic Evaluation Study (Cheer Compliant) Laser Prostatectomy for Benign Prostatic Hyperplasia: Outcomes and Cost-effectiveness

Mon, 01 Feb 2016 06:00:00 +0100

Abstract: To determine which surgical treatment for lower urinary tract symptoms, which is suggestive of benign prostatic hyperplasia (BPH), is more cost-effective and yields a better patient's preference. Treatment outcome, cost, and perioperative complications to assess the treatment effectiveness of using laser prostatectomy as a treatment for BPH were investigated in this study. This retrospective study included 100 patients who underwent transurethral resection of prostate (TUR-P) and another 100 patients who received high-powered 120 W (GreenLight HPS) laser prostatectomy between 2005 and 2011. International Prostate Symptom Score and uroflow parameters were collected before the surgery and the uroflow and postvoiding residual volumes were evaluated before treatment and at 3, 6, ...



Inflammatory response of a prostate stromal cell line induced by Trichomonas vaginalis

Mon, 01 Feb 2016 00:00:00 +0100

This study is the first attempt to demonstrate an inflammatory reaction in prostate stromal cells caused by T. vaginalis. This article is protected by copyright. All rights reserved. (Source: Parasite Immunology)



Male hormones and men's quality of life

Sat, 30 Jan 2016 17:20:32 +0100

Purpose of review: Male hormones can significantly impact a man's quality of life. Recently, there has been controversy with the use of testosterone and its impact on a man's quality of life. These controversies include testosterone's effect on cardiovascular disease, benign prostatic hyperplasia, prostate cancer, and fertility. The purpose of this manuscript is to further evaluate mainly testosterone's effect in these controversial areas as well as testosterone's overall effect on a man's quality of life. Recent findings: Recent findings suggest that testosterone does not increase a man's risk of developing benign prostatic hyperplasia or prostate cancer. Men with low testosterone levels are more likely to suffer a cardiovascular event and develop insulin resistance. Exogenous testostero...



Transitional Zone Index as a Predictor of the Efficacy of α-Blocker and 5α-Reductase Inhibitor Combination Therapy in Korean Patients with Benign Prostatic Hyperplasia

Sat, 30 Jan 2016 17:20:09 +0100

Conclusions: Greater Qmax improvement is expected with combination therapy comprising α-blockers and 5α-reductase inhibitors for patients with a TZI ≥0.5. The TZI may be useful for predicting the Qmax response to combination treatment for BPH.Urol Int (Source: Urologia Internationalis)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Crossing a Prostatic Artery Chronic Total Occlusion to Perform Prostatic Arterial Embolization

Sat, 30 Jan 2016 14:06:55 +0100

We present our experience of crossing an occluded prostatic artery to perform PAE successfully. (Source: Journal of Vascular and Interventional Radiology : JVIR)



The Urolift System for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A NICE Medical Technology Guidance

Sat, 30 Jan 2016 00:00:00 +0100

Abstract As part of its Medical Technologies Evaluation Programme (MTEP), the National Institute for Health and Care Excellence (NICE) invited Neotract (manufacturer) to submit clinical and economic evidence for their prostatic urethral lift device, Urolift, for the relief of lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS BPH). The Urolift System uses implants to retract the prostatic lobe away from the urethral lumen. The clinical evidence used in the manufacturer’s submission shows that Urolift is effective for the treatment of BPH. Urolift delivers a weighted mean International Prostate Symptom Score (IPSS) improvement of between 9.22 and 11.82 points. These Urolift improvements are greater than a published ‘marked improvement’ in IPSS score ...



Meta-analysis of metabolic syndrome and benign prostatic hyperplasia in Chinese patients

Fri, 29 Jan 2016 04:19:58 +0100

Conclusions This meta-analysis supports that the presence of MetS increases total prostate volume and annual prostate growth rate in Chinese BPH patients. Future studies are needed to explain the detailed underlying mechanisms. (Source: World Journal of Urology)



Prostate extracellular vesicles in patient plasma as a liquid biopsy platform for prostate cancer using nanoscale flow cytometry.

Thu, 28 Jan 2016 17:59:02 +0100

CONCLUSIONS: PMP enumeration was able to identify patients with Gleason Score ≥8 PCa but not patients with Gleason Score 4+3 PCa, but offers greater confidence than CTC counts in identifying patients with metastatic prostate cancer. CTC Subclass analysis was also not effective for post-prostatectomy follow up and for distinguishing metastatic PCa and localized PCa patients. Nanoscale flow cytometry of PMPs presents an emerging biomarker platform for various stages of prostate cancer. PMID: 26814433 [PubMed - as supplied by publisher] (Source: Oncotarget)



A comparative study of diode laser and plasmakinetic in transurethral enucleation of the prostate for treating large volume benign prostatic hyperplasia: a randomized clinical trial with 12-month follow-up

Thu, 28 Jan 2016 00:00:00 +0100

The objective of this study is to compare the efficacy and safety of diode laser enucleation of the prostate (DiLEP) with plasmakinetic enucleation of the prostate (PKEP) for symptomatic benign prostatic hyperplasia (BPH) patients with large prostate (volume > 80 ml). From January 2013 to June 2014, 80 consecutive patients were randomized treated with DiLEP (n = 40) or PKEP (n = 40). Perioperative and postoperative outcome data were assessed during a 1-year follow-up. There were no significant preoperative differences between the two surgical groups. The mean prostate volumes in the DiLEP and PKEP groups were 98.6 and 93.3 ml, respectively. DiLEP was equivalent to PKEP in improvement in International Prostate Symptom Score (IPSS), quality of life scores, and maximum flow r...

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Prostatic artery embolization for the treatment of symptomatic benign prostatic hyperplasia in men ≥75 years: a prospective single-center study

Wed, 27 Jan 2016 00:00:00 +0100

Conclusion PAE could be used as an effective, safe, and well tolerable method in the treatment of elderly symptomatic BPH patients, similarly to younger patients, and it may play an important role in patients in whom medical therapy has failed, who are at high surgical and anesthetic risk or who refuse the standard surgical therapy. (Source: World Journal of Urology)



[Value of suprapubic cystostomy in bipolar transurethral resection of the prostate for benign prostatic hyperplasia below 80 gram].

Tue, 26 Jan 2016 13:00:02 +0100

CONCLUSIONS: In B-TURP for BPH below the weight of 80 g, suprapubic cystostomy is associated with a longer time for operation, bladder washing, catheter indwelling and postoperative hospital stay, and thus provides no obvious benefits for the patients. PMID: 26806753 [PubMed - as supplied by publisher] (Source: Journal of Southern Medical University)



5‐alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial

Mon, 25 Jan 2016 00:00:00 +0100

This article is protected by copyright. All rights reserved. (Source: International Journal of Cancer)



Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment—the QUALIPROST study

Mon, 25 Jan 2016 00:00:00 +0100

Conclusions Improvements in QoL and symptoms were equivalent across the medical treatments most widely used in real-life practice to manage patients with moderate or severe LUTS. HESr showed an equivalent efficacy to AB and 5ARI with fewer side effects. (Source: International Urology and Nephrology)



Benign prostatic hyperplasia and lower urinary tract symptoms. A review of current evidence.

Mon, 25 Jan 2016 00:00:00 +0100

CONCLUSIONS: The availability of drugs that can act on the various LUTS helps integrate the pathophysiological paradigm into the functional one, providing more appropriate treatment for our patients. PMID: 26823069 [PubMed - as supplied by publisher] (Source: Actas Urologicas Espanolas)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Molecules, Vol. 21, Pages 137: Antiproliferative Effects of New Dimeric Ellagitannin from Cornus alba in Prostate Cancer Cells Including Apoptosis-Related S-Phase Arrest

Sat, 23 Jan 2016 00:00:00 +0100

Activity-guided isolation of 80% acetone extract of Cornus alba, which is traditionally used as an anti-inflammatory, hemostatic and diuretic in Korea, yielded one novel compound, tentatively designated cornusiin H (13), together with 12 known compounds. The known compounds included four flavonoids (catechin (1), quercetin-3-O-β-d-glucuronide (2), quercetin-3-O-β-d-glucopyranoside (3), kaempferol-3-O-β-d-glucopyranoside (4)) and eight hydrolysable tannins (gallic acid (5), 2,6-di-O-galloyl-hamamelofuranoside (6), 2-galloyl-4-caffeoyl-l-threonic acid (7) 2,3-di-O-galloyl-4-caffeoyl-l-threonic acid (8), 1,2,3,4,6-penta-O-galloyl-β-d-glucopyranoside (9), cornusiin B (10), cornusiin A (11) and camptothin B (12)). All compounds exhibited potent 1,1-diphenyl-2-picrylhydrazyl (DPPH)-free radi...



Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

Fri, 22 Jan 2016 00:00:00 +0100

Conclusions PDE5-Is are safe and effective in improving both LUTS and erectile function in appropriately selected men with LUTS/BPE. Data on the reduction of disease progression, long-term outcomes, and cost-effectiveness analyses are still lacking. Patient summary We reviewed recent literature on phosphodiesterase type 5 inhibitors in men with lower urinary tract symptoms associated with prostatic enlargement. We found evidence to confirm that phosphodiesterase type 5 inhibitors are a valid treatment option for men affected by bothersome urinary symptoms with or without erectile dysfunction. Phosphodiesterase-type-5 inhibitors are safe and effective in improving both urinary symptoms and erectile function in appropriately selected men with lower urinary tract symptoms/benign prostatic en...



Re: Benign Prostatic Hyperplasia Related Content on YouTube: Unregulated and Concerning

Fri, 22 Jan 2016 00:00:00 +0100

R. Tanwar, N. Khattar, R. Sood and A. Makkar (Source: The Journal of Urology)



Re: Prevalence of Inflammation and Benign Prostatic Hyperplasia on Autopsy in Asian and Caucasian Men

Fri, 22 Jan 2016 00:00:00 +0100

A. R. Zlotta, S. Egawa, D. Pushkar, A. Govorov, T. Kimura, M. Kido, H. Takahashi, C. Kuk, M. Kovylina, N. Aldaoud, N. Fleshner, A. Finelli, L. Klotz, G. Lockwood, J. Sykes and T. V. Kwast (Source: The Journal of Urology)



[Correlation of IL-8 and IL-6 in prostatic fluid with serum prostate-specific antigen level in patients with benign prostatic hyperplasia complicated by prostatitis].

Wed, 20 Jan 2016 00:00:00 +0100

CONCLUSION: Prostatitis is an important risk factor for elevated serum PSA level in patients with BPH, and both IL-8 and IL-6 levels in the prostatic fluid are correlated with serum PSA level. PMID: 26806754 [PubMed - in process] (Source: Journal of Southern Medical University)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




[Restriction landmark genomic scanning for screening aberrant CpG methylations in prostate cancer].

Wed, 20 Jan 2016 00:00:00 +0100

CONCLUSION: Among all the tested CpG islands, 10245 (37.2%) in prostate cancer and 8658 (30.3%) in BPH samples were found to be abnormally methylated, and >60% of the methylated CpG islands were in the promoter region. Compared with BPH samples, the prostate cancer samples showed differential methyation in 735 CpG islands, including 458 hepermethyated and 256 hypomethelated ones. Seven genes (DPYS, P16, APC, GSTP1, TMEM122, RARB, and ARHGAP20) in prostate cancer were identified to have distinct methylations. Bioinformatics analysis suggested that these genes were associated with several biomolecular and biological processes, and among them DPYS gene was involved in 13 GO anotated biologic functions, development of 50 diseases and 47 protein interactions. Pyrosequencing of 7 sites of the...



Men with severe lower urinary tract symptoms are at increased risk of depression - Jeong WS, Choi HY, Nam JW, Kim SA, Choi BY, Moon HS, Kim KS.

Mon, 18 Jan 2016 21:15:44 +0100

PURPOSE: Lower urinary tract symptoms (LUTS) comprise a set of common, bothersome symptoms in middle-aged and elderly men. Recent research suggests that depressive symptoms may influence the symptoms of benign prostatic hyperplasia (BPH). We performed a co... (Source: SafetyLit)



Predictive values of vascular endothelial growth factor and microvessel-density levels in initial biopsy for prostate cancer

Mon, 18 Jan 2016 00:00:00 +0100

Publication date: Available online 16 January 2016 Source:The Kaohsiung Journal of Medical Sciences Author(s): Enis Kervancioglu, Murat Kosan, Hilal Erinanc, Umut Gonulalan, Ahmet Ibrahim Oguzulgen, Esra Zeynep Coskun, Hakan Ozkardes Angiogenesis is an important factor in the development and progression of prostate cancer (PCA). We aimed to investigate the values of vascular-endothelial-growth-factor (VEGF) expression level and microvessel density (MVD) in the prediction of PCA diagnosis at repeated prostate biopsy (re-PBx). We retrospectively evaluated 167 patients with re-PBx according to elevated prostate-specific antigen levels, suspicious digital rectal examination, and the presence of premalignant lesions. Patients with PCA on re-PBx were included in the cancer group (n = ...



Reply

Mon, 18 Jan 2016 00:00:00 +0100

The conclusions of our study are the following: (1) tamsulosin, an alpha blocker, is beneficial for relieving lower urinary tract symptoms (LUTS) and for improving some symptoms of metabolic syndrome factors; and (2) tamsulosin is also beneficial in resolving LUTS-benign prostatic hyperplasia (BPH) in patients with metabolic syndrome factors. (Source: Urology)



Editorial Comment

Mon, 18 Jan 2016 00:00:00 +0100

Metabolic syndrome is a huge health problem not only in Korea, as documented in this study, but also in the United States. In 2010, the prevalence of male and female adults who were overweight and obese was 74% and 65%, respectively.1 Recent studies have demonstrated a significant correlation between obesity and benign prostatic hyperplasia exacerbating lower urinary tract symptoms (LUTS).2 (Source: Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Author Reply

Mon, 18 Jan 2016 00:00:00 +0100

The conclusions of our study are the following: (1) tamsulosin, an alpha blocker, is beneficial for relieving lower urinary tract symptoms (LUTS) and for improving some symptoms of metabolic syndrome factors; and (2) tamsulosin is also beneficial in resolving LUTS-benign prostatic hyperplasia (BPH) in patients with metabolic syndrome factors. (Source: Urology)



Urodynamic Assessments of Bladder Outflow Obstruction Associated with Benign Prostatic Hyperplasia

Sun, 17 Jan 2016 19:15:32 +0100

(Source: Journal of Mens Health)



Effects of Dexmedetomidine Infusion on the Recovery Profiles of Patients Undergoing Transurethral Resection.

Sat, 16 Jan 2016 17:44:03 +0100

Authors: Kwon SY, Joo JD, Cheon GY, Oh HS, In JH Abstract Transurethral resection has been the gold standard in the operative management of benign prostatic hyperplasia and bladder tumor; however, it is associated with several complications that may cause patient discomfort. We evaluated the usefulness of continuous infusion of dexmedetomidine on emergence agitation, hemodynamic status, and recovery profiles in patients undergoing elective surgery by a randomized clinical trial. Sixty patients aged 30 to 80 yr who were scheduled for elective transurethral resection under general anesthesia were included in this study. Participants were randomly assigned to two groups (control group, group C; dexmedetomidine group, group D). A total of 60 male patients were enrolled in this study an...



Erectile dysfunction (ED) and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12‐weeks of treatment

Thu, 14 Jan 2016 06:45:09 +0100

ConclusionsThis novel measure of combined response is useful in differentiating patients with clinically relevant symptom improvement for both ED and LUTS/BPH following treatment with tadalafil 5mg once‐daily versus placebo. This combined responder measure may be useful in future assessment of treatment benefits across patient groups following various types of treatment intervention (e.g., surgical vs pharmacotherapy vs non‐pharmacologic intervention).This article is protected by copyright. All rights reserved. (Source: BJU International)



Abstract A16: Different epigenetic mechanisms involved in the regulation of SFRP1 gene in prostate cancer

Thu, 14 Jan 2016 00:00:00 +0100

Among men, prostate cancer (PCa)[1] is the second most common cancer and the fifth cause of death worldwide [2]. Androgens play an important role in the development of the disease. For advanced PCa the standard therapy is androgen depletion. However, after 2 or 3 years a high percentage of patients become resistant to this therapy and castration resistant prostate cancer (CRPC) is developed. There is no successful treatment for CRPC, leading into death [3, 4]. Wingless pathway (WNT) is aberrantly activated in several cancer types and in PCa it is involved in AR activity modulation, promoting cancer development [5]. Secreted Frizzled Related Protein 1 (SFRP1) is commonly known as a WNT inhibitor and generally proposed as a tumor suppressor gene. SFRP1 can exert its tumor suppressor activity...

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Choline-phospholipids inter-conversion is altered in elderly patients with prostate cancer.

Thu, 14 Jan 2016 00:00:00 +0100

CONCLUSIONS: The current results support systemic alterations in phospholipids metabolism in PCa. We report on a significant decrease in plasma concentrations of sphingomyelin in elderly patients with PCa and in users of statins. The PCa-associated low sphingomyelin showed a synergy with the effect of statins. The presence of PCa was not associated with significant changes in plasma concentrations of choline or methyl metabolites. However, changes in choline absorption and tissue uptake cannot be ruled out in this study. PMID: 26776756 [PubMed - as supplied by publisher] (Source: Biochimie)



Management of male lower urinary tract symptoms/benign prostatic hyperplasia

Tue, 12 Jan 2016 00:00:00 +0100

Volume 195, Number 1, Page 127, Statistical Analysis: Sentence 2 should state, “If the lower limit of the CI was 85% or greater, it was concluded that the primary analysis for self-selection had been achieved.” (Source: The Journal of Urology)



A possible relationship between serum sex hormones and benign prostatic hyperplasia/lower urinary tract symptoms in men who underwent transurethral prostate resection.

Tue, 12 Jan 2016 00:00:00 +0100

In this study, we examined the relationship between sex hormone levels and lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH) who underwent transurethral surgery. The study was conducted in 158 patients who came to our hospital for surgery. Clinical conditions were assessed by body mass index (BMI), digital rectal examination, International Prostate Symptom Score (IPSS) and transrectal ultrasound (TRUS). The levels of sex hormones (including total testosterone (TT), estradiol (E 2 ), progesterone (P), luteinizing hormone (LH), follicle-stimulating hormone (FSH) and prolactin (PRL)) and prostate-specific antigen (PSA) were reviewed. Correlations were determined through statistical analysis. The mean age was 72.06 ± 8.68 years. The total IPSS was significantl...



Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome

Tue, 12 Jan 2016 00:00:00 +0100

Nature Reviews Urology 13, 108 (2016). doi:10.1038/nrurol.2015.301 Authors: Linda Vignozzi, Mauro Gacci & Mario Maggi Epidemiological studies have shown that age is the principal unmodifiable risk factor of lower urinary tract symptoms (LUTS). Until the past decade, the process of lower urinary tract ageing was, therefore, considered unmodifiable — as ageing per se. However, the traditional dogma that BPH-related (Source: Nature Reviews Urology)